These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 2964031)
1. [Efficacy of pipobroman in the treatment of essential thrombocythemia]. Bauters F; Jouet JP; Simon M; Pollet JP; Fenaux P; Walter MP Presse Med; 1988 Jan; 17(2):81. PubMed ID: 2964031 [No Abstract] [Full Text] [Related]
2. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients. Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969 [TBL] [Abstract][Full Text] [Related]
3. Pipobroman therapy of essential thrombocythemia. Mazzucconi MG; Francesconi M; Chistolini A; Falcione E; Ferrari A; Tirindelli MC; Mandelli F Scand J Haematol; 1986 Oct; 37(4):306-9. PubMed ID: 3787181 [TBL] [Abstract][Full Text] [Related]
4. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug. Passamonti F; Cazzola M Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447 [No Abstract] [Full Text] [Related]
5. Pregnancy in a young woman affected by essential thrombocythemia: a case report. Ferrari A; Mazzucconi MG; Martinelli E; Giona F; Paesano R; Pachi A Haematologica; 1989; 74(1):115-6. PubMed ID: 2498176 [No Abstract] [Full Text] [Related]
6. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman. Messora C; Bensi L; Vanzanelli P; Temperani P; Carotenuto M; Sacchi S Haematologica; 1996; 81(1):51-3. PubMed ID: 8900853 [TBL] [Abstract][Full Text] [Related]
7. Bone marrow aplasia after pipobroman: an immune-mediated mechanism? Triffet A; Straetmans N; Ferrant A Br J Haematol; 2001 Dec; 115(3):713-4. PubMed ID: 11736962 [No Abstract] [Full Text] [Related]
8. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Passamonti F; Malabarba L; Orlandi E; Pascutto C; Brusamolino E; Astori C; Baratè C; Canevari A; Corso A; Bernasconi P; Cazzola M; Lazzarino M Br J Haematol; 2002 Mar; 116(4):855-61. PubMed ID: 11886392 [TBL] [Abstract][Full Text] [Related]
9. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617 [TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Passamonti F; Rumi E; Malabarba L; Arcaini L; Orlandi E; Brusamolino E; Pascutto C; Cazzola M; Lazzarino M Ann Hematol; 2004 Aug; 83(8):495-7. PubMed ID: 15175894 [No Abstract] [Full Text] [Related]
11. Practical approach to treating essential thrombocythaemia: case studies. Reilly JT Eur J Haematol Suppl; 2007 Oct; (68):40-2. PubMed ID: 17727566 [No Abstract] [Full Text] [Related]
12. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295 [TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360 [TBL] [Abstract][Full Text] [Related]